JNK

Tanzisertib (CC-930) (CC-930) is a potent inhibitor of JNK1/2/3 with IC50s of 61/7/6 nM, respectively, with potential antifibrotic activity.

Metacetamol, a non-toxic acetaminophen derivative, is an OTC analgesic/antipyretic and synthesis intermediate.

Mefloquine hydrochloride (Mefloquin hydrochloride) is a quinoline derivative used for the prevention and therapy of P. falciparum malaria.

Urolithin B is one of the gut microbial metabolites of ellagitannins and is found in diverse plant foods, including pomegranates, berries, walnuts, tropical

NBDHEX is a potent inhibitor of glutathione S-transferase P1-1 (GSTP1-1).

SU3327 (halicin) is a potent, selective and substrate-competitive inhibitor of JNK(IC50 of 0.7 μM).

Chloramphenicol (Chloromycetin) is a broad-spectrum antibiotic that inhibits the biosynthesis of bacterial proteins. Cost-effective and quality-assured.

Fasudil (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK.

AS601245.2TFA (345987-15-7 free base) (AS601245.2TFA) is a cell-permeable Inhibitor of JNK (IC50s of 150, 220, and 70 nM for hJNK1, hJNK2, and hJNK3,

JNK3 inhibitor-8: potent, selective, oral, BBB-penetrating, IC50: JNK3=21 nM, JNK2=2203 nM, JNK1>10,000 nM; potential in Alzheimer's research.

"JNK-1-IN-2 (Compound c6) is a potent inhibitor of JNK-1 with an IC50 of 33.5 nM, and also exhibits inhibitory effects on JNK-2 and JNK-3 with IC50 values of

L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK, it has been shown to effectively inhibit JNK activity in in vivo studies.

SET-171 is a JNK (c-Jun N-terminal kinase) inhibitor that exhibits significant anticancer activity by suppressing the expression of hepatic pyruvate kinase (PKL) and offers potential in regulating lipid metabolism. In antitumor studies, SET-171 shows notable cytotoxicity against human liver cancer cell lines HepG2 and Huh7, with IC50 values of 8.82 μM and 2.97 μM, respectively. Additionally, in research related to non-alcoholic fatty liver disease (NAFLD), SET-171 significantly reduces triglyceride (TAG) levels and inhibits the expression of proteins associated with steatosis. This compound holds promise for hepatocellular carcinoma (HCC) and NAFLD research.

JNK-IN-18 (compound 23b) is a potent inhibitor of JNK1, boasting an IC50 of 2 nM. It demonstrates superior efficacy when compared to its IC50 values of 125 nM for JNK2 and 98 nM for BRAF(V600E).

N-Butyl α-D-fructofuranoside, extracted from the root barks of Ulmus davidiana var.

OVA-E1 peptide TFA activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes.

OVA-E1 peptide, as SIINFEKL variant, triggers similar p38/JNK activation in mutant and normal thymocytes.

IQ-1S is an inhibitor of NF-κB/activating protein 1 (AP-1) with an IC50 of 1.8 μM. It exhibits high binding affinity to all three JNKs, with Kd values for JNK3, JNK2, and JNK1 being 87 nM, 360 nM, and 390 nM, respectively.

PROTAC JNK1-targeted-1 (PA2) is a JNK1 PROTAC degrader with a DC50 of 10 nM. It effectively reduces fibronectin levels and is useful in lung fibrosis research. [Pink: JNK1 inhibitor; Black: linker; Blue: CRBN Ligand]

JNK2-IN-1 (Compound J27), a selective JNK2 inhibitor with a dissociation constant (Kd) of 79.2 µM, exhibits anti-inflammatory effects by attenuating TNF-α and

JNK-IN-12 (compound P2) is a mitochondrial-targeted JNK inhibitor with an IC50 value of 66.3 nM, comprising a mitochondrial-specific cell-penetrating peptide

JTP10-△-TATi TFA is a selective inhibitor of JNK2 peptide (IC50: 92 nM), exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3.

Salicortin, a phenolic glycoside from Populus and Salix, has anti-adipogenic, anti-amnesic, and immune effects.

JNK-1-IN-3 (Compound 9e) downregulates JNK1 and phosphorylated JNK1, reduces c-Jun and c-Fos expression in tumours, and restores p53 activity.

JTP10-△-R9 TFA is a selective inhibitor of JNK2 peptide (IC50: 89 nM), exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3.

Vacquinol-1 is an MKK4 activator, which rapidly and selectively induces glioma cell death.

JNK-IN-14 is a potent inhibitor of JNK with IC50 values of 1.81 nM for JNK1, 12.7 nM for JNK2, and 10.5 nM for JNK3.

BSO-07 is a ROS/JNK activator that exhibits potent anti-cancer properties, demonstrated by an IC50 of 24.81 μM in human breast cancer (BC) cells. The mechanism of action for BSO-07 involves JNK activation and the promotion of increased ROS levels, which lead to the induction of apoptosis (Apoptosis) and tumorigenic apoptosis. This includes enhanced expression of apoptosis-related proteins such as PARP, Bax, phosphorylated p53, ATF4, and CHOP, along with a reduction in the levels of anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL, and Survivin). BSO-07 holds promise for research in the field of breast cancer.

A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;

Peptide based on JIP-1(153-163) inhibits JNK with micromolar affinity; barely affects p38, ERK.

D-JNKI-1 (AM-111) is a highly effective and cell-permeable peptide inhibitor.

Potent, oral JNK3 inhibitor-7 crosses blood-brain barrier, IC50: 53 nM (JNK3), offers neuroprotection, potential in AD research.

MAP4K4-IN-6 (Compound 15f) is a MAP4K4 inhibitor with an IC50 of 80 nM. It reduces the phosphorylation of c-Jun and exhibits neuroprotective effects. Additionally, MAP4K4-IN-6 enhances the vitality of motor neurons and can be utilized in the study of amyotrophic lateral sclerosis (ALS).

D-JBD19 is a non-permeable peptide with neuroprotective effects.

A unique collection of 365 compounds targeting MAPK signaling for drug discovery in MAPK related diseases;

Ezatiostat (TER199(free base)) is a tripeptide analog of glutathione that can selectively inhibit GSTP1-1 catalytic activity.

Mitogen-activated protein kinase 8 (MAPK8), also known as JNK1, is a member of the MAP kinase family.

Ro 31-8220: potent PKC inhibitor (IC50: 5-27 nM). Affects MAPKAP-K1b, MSK1, S6K1, GSK3β (IC50: 3-38 nM), not MKK3/4/6/7.

Loureirin B suppresses fibrosis by modulating MMPs/TIMPs, hindering fibroblast growth, and targeting TGF-β1/Smad2/3 pathway.

Taurochenodeoxycholic Acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid.

Bentamapimod (AS 602801) is a novel, orally active inhibitor of JNK.

Anisomycin (NSC-76712), an antibiotic from Streptomyces, blocks protein/DNA synthesis by targeting peptidyl transferase/80S ribosomes.

Actein stimulates bone formation, counters osteoporosis and oxidative damage, and may treat lipid disorders and cancer, inhibiting breast cancer cell growth.

JNK peptide inhibitor. Mimics JIP-1 residues 153-163. Micromolar affinity, little effect on p38, ERK.

JNK-IN-7 (JNK inhibitor) is a selective JNK1/2/3 inhibitor (IC50: 1.54/1.99/0.75 nM).

JNK Inhibitor VIII (TCS JNK 6o) is an ATP-competitive selective inhibitor of c-Jun N-terminal kinase (JNK)(IC50 values of 45 nM and 160 nM for JNK-1 and -2,